On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Kaival Brands Innovations Group Inc. (KAVL) Acquires Patent, Announces Lab, Enters Smoking Cessation Market

  • KAVL recently acquired patent, announced creation of wholly owned subsidiary to develop smoking cessation products.
  • Company plans to create products that satisfy smokers but are free from nicotine’s addictive traits.
  • CEO says company is excited to help “all nicotine users lead healthier and higher-quality lives.”

The Centers for Disease Control and Prevention report that smoking is the leading cause of preventable death in the world today (https://ibn.fm/dxZ1W). With the help of new and innovative cessation products, the  7 million deaths that occur every year due to smoking could be prevented — and Kaival Brands Innovations Group (OTCQB: KAVL) is determined to do all it can to make it happen.

A company focused on growing and incubating innovative and profitable products into mature, dominant brands, Kaival Brands has turned its attention to the smoking cessation space (https://ibn.fm/t3k6S). The company recently acquired a patent covering the creation of all synthetic nicotine smoking cessation and synthetic nicotine addiction therapy products. In addition, the company has announced the creation of a wholly owned subsidiary — Kaival Labs — that will own the patent and develop associated products.

“The science behind these patents has discovered that within the nicotine molecule, the S-isomers control the addictive properties, whereas the R-isomers control the beneficial qualities of the nicotine that a user enjoys,” said Kaival Brands CEO Niraj Patel. “The exclusivity is that the patents allow us to control the specific ratios of each isomer in the final synthetic nicotine molecule we produce for cessation products. We can now create completely unique products for smoking cessation and nicotine addiction therapy that remain effective and satisfying for the user, but are free from nicotine’s addictive traits.

“Kaival Labs will own the patented science to create a pure, yet nonaddictive synthetic nicotine for the development and production of smoking cessation and nicotine replacement therapy products,” Patel continued. “Tobacco-Free Nicotine (‘TFN’) is a certified clean, pure, non-tobacco-derived synthetic nicotine, and a key ingredient in numerous products like nicotine patches, lozenges, gums, vape sticks, e-liquids and more.”

Efforts to help smokers who are seeking to quit — including products such as chewing gum, inhalers, lozenges, patches, sprays and sublingual tablets, and therapies such as nicotine replacement therapy (“NRT”), non-NRT therapy and e-cigarettes — are not new. However, until now, they were fairly ineffective. A National Health Information Survey reports that while 34.2 million U.S. adults smoke, an estimated 70% of them want to quit — and 55% of them have tried to kick the habit in the last year (https://ibn.fm/cgBHr). Unfortunately, the success rate for quitting is under 10% because nicotine is so addictive.

Because Kaival Brands’ newly acquired patent provides the ability to control levels of both the S-isomers and the R-isomers in the nicotine molecule, the company intends to formulate and offer patented, true step-down products that reduce nicotine addiction levels without decreasing the benefits.

“Smokers and tobacco users worldwide are looking for an answer and a real solution to their nicotine addiction problems,” Patel said. “Imagine patent-protected products, either approved pharmaceutically or made available over the counter, that offered a way to truly ease a user off their addictive cravings for nicotine without losing any of their accustomed benefits along the way. We are excited to develop these innovative patents and bring effective, enjoyable smoking cessation products to market, helping all nicotine users lead healthier and higher-quality lives.”

Kaival Brands is a fast-growing company focused on generating wealth by seeking to incubate innovative products into mature and dominant brands in their respective markets. Our vision is to develop internally, acquire or own, and exclusively distribute these profitable brands with recognizable innovation and superior quality.

For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

From Our Blog

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Obtains Patent for Mustard-Derived Fumigation of Stored Vegetables, Grains

December 4, 2020

Alternatives to potato sprout inhibition in critical need as U.S. moves towards eliminating CIPC CIPC, leading agrochemical product used for sprout suppression, was banned by EU in October MGRO’s patent focused on controlling vegetable, potato sprouting without harmful synthetic chemicals MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has been granted an exclusive patent licensing […]

Rotate your device 90° to view site.